Document Detail

The impact of matrix metalloproteinases and their tissue inhibitors in inflammatory bowel diseases.
MedLine Citation:
PMID:  22722554     Owner:  NLM     Status:  In-Data-Review    
Background: It has been suggested that matrix metalloproteinases (MMPs) may play a role in the pathogenesis of inflammatory bowel diseases (IBD). However, the impact of serum MMPs and their inhibitors [tissue inhibitors of metalloproteinases (TIMPs)] have scarcely been investigated in the same experimental setting in ulcerative colitis (UC) and Crohn's disease (CD) as well as their correlation with IBD activity. Methods: MMP-2, MMP-7, MMP-9, TIMP-1 and TIMP-2 serum antigen levels were determined in 23 patients with UC, 25 patients with CD and 10 healthy control patients by enzyme-linked immunoassay technique. Statistical analysis with one-way ANOVA and Student's t tests was performed. A linear regression analysis or a Spearman's r test was used to assess correlation. Differences were considered significant with p < 0.05. Results: Serum antigen concentrations of MMP-9, TIMP-1 and TIMP-2 were significantly higher in UC and CD patients compared to controls. MMP-7 was also significantly higher in CD compared with controls. Elevated MMP-9 and TIMP-1 antigen levels showed significant positive correlation with disease activity of IBD. MMP-2 and TIMP-2 levels inversely correlated with CD activity. Significant correlations were found between MMP-9/TIMP-1 and MMP-2/TIMP-2 antigen levels in both UC and CD. Conclusions: We demonstrated that serum antigen concentrations of MMP-9, TIMP-1 and TIMP-2 were significantly increased in patients with UC and CD compared to controls. Our results suggest that MMPs and TIMPs may contribute to the inflammatory and remodeling processes in IBD. Serum MMP-9 and TIMP-1 might be useful as additional biomarkers in the assessment of IBD activity.
Gábor Lakatos; István Hritz; Mária Zsófia Varga; Márk Juhász; Pál Miheller; Gabriel Cierny; Zsolt Tulassay; László Herszényi
Related Documents :
3751504 - Thymectomy in late-onset myasthenia gravis.
20655284 - On the frontline: what an optometrist needs to know about myasthenia gravis.
25388964 - Scd163 in aosd: a biomarker for macrophage activation related to hyperferritinemia.
373074 - Scanning electron microscopy of exudative macrophages in malignant lymphoma.
23732374 - Vitamin d receptor gene apai, taqi, foki and bsmi polymorphisms in a group of turkish p...
6783684 - Intravenous carbon dioxide as an echocardiographic contrast agent.
Publication Detail:
Type:  Journal Article     Date:  2012-06-20
Journal Detail:
Title:  Digestive diseases (Basel, Switzerland)     Volume:  30     ISSN:  1421-9875     ISO Abbreviation:  Dig Dis     Publication Date:  2012  
Date Detail:
Created Date:  2012-06-22     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8701186     Medline TA:  Dig Dis     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  289-95     Citation Subset:  IM    
Copyright Information:
Copyright © 2012 S. Karger AG, Basel.
2nd Department of Medicine, Semmelweis University, Budapest, Hungary.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Molecular targeted therapy in hepatocellular carcinoma: present achievements and future challenges.
Next Document:  Novel prognostic biomarkers in colorectal cancer.